Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 1 ... · Email from Clare Bloomfield, British Embassy, to Murray Lumpkin, FDA, re: UK request for information on sodium

Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 1 of 74


Administrative Record Index

Description Date Bates NumberLetter from Charles Ryan, Director, Arizona Department of Corrections, to David Thomas, FDA Investigations re: Execution by Lethal Injection of Arizona Inmate Jeffrey Timothy Landrigan #082157 9/24/2010 000001Letter from Charles Flanagan, Deputy Director, Arizona Department of Corrections, to David Thomas, FDA Investigations, enclosing Controlled Substance Registration Certificate 9/24/2010 000002-000003Notice of FDA Action 9/29/2010 000004Department of Treasury, U.S. Customs Service Entry/Immediate Delivery Form 10/7/2010 000005-00006FDA's Operational and Administrative System for Import Support (OASIS) Screenshot for Entry # 112-9247186-3 n/a 000007Letter from Dale Baich, Supervisor, Capital Habeas Unit, Office of the Federal Public Defender for the District of Arizona, to Ralph Tyler, Chief Counsel, FDA 10/23/2010 000008-000012Department of Homeland Security, U.S. Customs and Border Protection Entry/Immediate Delivery Form 10/25/2010 000013-000015FDA's OASIS Screenshot for Entry # 574-0251126-5 n/a 000016Email from Patrick Bowen, FDA, to Distribution re: Import Bulletin #60-B08 10/27/2010 000017-000018Email from Nima Abbaszadeh, U.K. Desk Officer, U.S. Department of State, to Ilisa Bernstein re: assistance on sodium thiopental question raised by UK Embassy, enclosing Letter from Ian Bond, Political Counsellor, British Embassy Washington, to Elizabeth Dibble, Deputy Assistant Secretary of State 11/4/2011 000019-000020Email from Clare Bloomfield, British Embassy, to Murray Lumpkin, FDA, re: UK request for information on sodium thiopental 11/4/2010 000021Email from Tom Smith, Department for Business, Innovation and Skills, to Murray Lumpkin re: Sodium Thiopental 11/5/2010 000022Email from Murray Lumpkin to Tom Smith cc JM Sharfstein and Margaret Hamburg re: Substantive response from US FDA re: Sodium Thiopental 11/16/2010 000023-000024Letter from Charles Ryan, Director, Arizona Department of Corrections, to Deborah Autor, Director, Office of Compliance, CDER, re: Entry #574-0251126-5 Thiopental Sodium 11/10/2010 000025-000026

1 of 2


Administrative Record Index

Letter from Charles Ryan, Director, Arizona Department of Corrections, to David Thomas, FDA Investigations, re: Inspection and Release of Entry #574-0251126-5, Thiopental Sodium 11/10/2010 000027Letter from Dale Baich, Supervisor, Capital Habeas Unit, Office of the Federal Public Defender for the District of Arizona, to Thomas Emerick, Assistant Special Agent in Charge, FDA 11/17/2010 000028-000029Department of Treasury Entry/Immediate Delivery Form 11/24/2010 000030-000031FDA's OASIS Screenshot for Entry # 112-9938358-2 n/a 000032Letter from Benjamin Rice, General Counsel, State of California, to Ruth Dixon, FDA 12/9/2010 000033Sodium Thiopental Statement, Key Messages 12/29/2010 000034-000035Email from Shelly Burgess to Nathan Koppel 1/4/2011 000036-000037Letter from Coleen Klasmeier, Bradford Berenson (Sidley Austin), and Dale Baich (Office of the Federal Public Defender for the District of Arizona), to Margaret Hamburg, Commissioner, FDA 1/4/2011 000038-000050Guidance for handling pending and future shipments of Sodium Thiopental 1/5/2011 000051-000057Notice of FDA Action 1/6/2011 000058-000059Notice of FDA Action 1/7/2011 000060-000061Letter from Patricia Shafer, Acting District Director, New Orleans District Office, to Benjamin Rice, Chief Counsel, California Department of Corrections & Rehabilitation 1/7/2011 000062-000063Letter from Alonza Cruse, District Director, Los Angeles District, to Carson McWilliams, Warden, Arizona State Prison Complex n/a 000064

MiscellaneousFDA Establishment Inspection Report for Sandoz - Endorsement Excerpt 7/8/2009 000065FDA Establishment Inspection Report for Sandoz - Summary Excerpt 7/29/2010 000066-000069Form FDA 483 - Inspectional Observations for Sandoz 7/29/2010 000070

2 of 2


FDA 000001

(b) (7)(E)


FDA 000002


FDA 000003


FDA 000004


FDA 000005

(b) (4)

(b) (4)

(b) (4)(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)(b) (4)(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (7)(C)


FDA 000006


FDA 000007


FDA 000008


FDA 000009


FDA 000010


FDA 000011


FDA 000012


FDA 000013


FDA 000014


FDA 000015

(b) (7)(E)


FDA 000016


FDA 000017


FDA 000018


FDA 000019


FDA 000020


FDA 000021


FDA 000022


FDA 000023


FDA 000024


FDA 000025


FDA 000026


(b) (7)(E)

FDA 000027


FDA 000028


FDA 000029


FDA 000030


FDA 000031


FDA 000032


FDA 000033


FDA 000034


FDA 000035


FDA 000036


FDA 000037


FDA 000038


FDA 000039


FDA 000040


FDA 000041


FDA 000042


FDA 000043


FDA 000044


FDA 000045


FDA 000046


FDA 000047


FDA 000048


FDA 000049


FDA 000050


FDA 000051


FDA 000052


FDA 000053


FDA 000054


FDA 000055


FDA 000056


FDA 000057


FDA 000058


FDA 000059


FDA 000060


FDA 000061


FDA 000062


FDA 000063


FDA 000064


FDA 000065


FDA 000066


FDA 000067


FDA 000068


FDA 000069


FDA 000070


Documents

Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 1 ... · Email from Clare Bloomfield, British Embassy, to Murray Lumpkin, FDA, re: UK request for information on sodium